Genetic variants in congenital long-QT disease genes are found in 10-15% of patients with drug-associated Torsades de Pointes, predominantly in genes encoding ancillary subunits.
DNA variants in the coding regions of congenital long-QT disease genes predisposing to aLQTS can be identified in approximately 10% to 15% of affected subjects, predominantly in genes encoding ancillary subunits.
Yang et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: